Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: A potential mechanism of altered leukemogenicity

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 2, 2012, Pages 203-212

  Härtel, Nicolai ^a   Klag, Thomas ^b   Hanfstein, Benjamin ^a   Mueller, Martin C ^a   Schenk, Thomas ^b   Erben, Philipp ^a   Hochhaus, Andreas ^b   La Rosée, Paul ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

BCR ABL; Cytokine; MAPK; Mutation; Resistance; Tyrosine kinase inhibitor

Indexed keywords

ABELSON KINASE; BREAKPOINT CLUSTER REGION PROTEIN; CD34 ANTIGEN; DASATINIB; IMATINIB; INTERLEUKIN 3; MITOGEN ACTIVATED PROTEIN KINASE; NILOTINIB;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMOGENESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; INTERLEUKIN-3; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; MYELOID CELLS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SRC-FAMILY KINASES; THIAZOLES;

EID: 84857053752     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-1086-x     Document Type: Article

References (43)

1. Apperley JF (2007) Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8: 1018-1029 (Pubitemid 47629897)
2. Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ (2008) Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol 15: 1109-1118
3. Bhatia R, McGlave PB, Dewald GW, Blazar BR, Verfaillie CM (1995) Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood 85: 3636-3645
4. Burchert A, Wang Y, Cai D et al (2005) Compensatory PI3-kinase/ Akt/mTor activation regulates imatinib resistance development. Leukemia 19: 1774-1782 (Pubitemid 41486155)
5. Chang F, Steelman LS, Lee JT et al (2003) Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17: 1263-1293 (Pubitemid 36857335)
6. Chu S, Holtz M, Gupta M, Bhatia R (2004) BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 103: 3167-3174 (Pubitemid 38451695)
7. Copland M, Hamilton A, Elrick LJ et al (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107: 4532-4539 (Pubitemid 43801382)
8. Cortez D, Reuther G, Pendergast AM (1997) The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene 15: 2333-2342 (Pubitemid 27496983)
9. Di Cristofano A, Niki M, Zhao M, Karnell FG, Clarkson B, Pear WS, Van Aelst L, Pandolfi PP (2001) p62 (dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210 (bcr-abl). J Exp Med 3: 275-284 (Pubitemid 32730802)
10. Dorsey JF, Cunnick JM, Lanehart R et al (2002) Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. Leukemia 16: 1589-1595
11. Druker BJ, Tamura S, Buchdunger E et al (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Medic 2: 561-566
12. Druker BJ, Guilhot F, O'Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417 (Pubitemid 44903745)
13. Fabian MA, Biggs WH III, Treiber DK et al (2005) A small moleculekinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23: 329-336 (Pubitemid 41094421)
14. Fedorov O, Marsden B, Pogacic V et al (2007) A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci USA 104: 20523-20528
15. Griswold IJ, MacPartlin M, Bumm T et al (2006) Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 26: 6082-6093 (Pubitemid 44204527)
16. Hanfstein B, Mueller MC, Kreil S et al (2011) Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy. Haematologica 96 (3): 360-366
17. Hantschel O, Wiesner S, Guttler T et al (2005) Structural basis for the cytoskeletal association of Bcr-Abl/c-Abl. Mol Cell 19: 461-473 (Pubitemid 41140004)
18. Hentschel J, Rubio I, Eberhart M et al (2011) BCR-ABL- and Rasindependent activation of Raf as a novel mechanism of Imatinib resistance in CML. Int J Oncol 39: 585-591
19. Hochhaus A, La Rosée P (2004) Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 18: 1321-1331 (Pubitemid 39136739)
20. Jabbour E, Kantarjian H, Jones D et al (2008) Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112: 53-55
21. Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL (2007) Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 109: 4016-4019 (Pubitemid 46641755)
22. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boqué C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 24: 2260-2270
23. Konig H, Copland M, Chu S et al (2008a) Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res 68: 9624-9633
24. Konig H, Holtz M, Modi H et al (2008b) Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia 22: 748-755 (Pubitemid 351552624)
25. La Rosee P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ (2002a) Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res 62: 7149-7153 (Pubitemid 36025227)
26. La Rosee P, O'Dwyer ME, Druker BJ (2002b) Insights from preclinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia 16: 1213-1219
27. La Rosee P, Johnson K, Corbin AS et al (2004) In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood 103: 208-215 (Pubitemid 38029940)
28. La Rosee P, Holm-Eriksen S, Konig H et al (2008) Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinibresistant chronic myeloid leukemia or Ph + acute lymphoblastic leukemia patients treated with nilotinib. Haematologica 93: 765-769 (Pubitemid 351669319)
29. Lahaye T, Riehm B, Berger U et al (2005) Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 103: 1659-1669 (Pubitemid 40490027)
30. Liu J, Joha S, Idziorek T et al (2008) BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism. Leukemia 22: 791-799 (Pubitemid 351552628)
31. Matulonis U, Salgia R, Okuda K, Druker B, Griffin JD (1993) Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp Hematol 21: 1460-1466 (Pubitemid 24215368)
32. McCubrey JA, Steelman LS, Abrams SL et al (2006) Roles of the RAF/MEK/ERK and PI3 K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46: 249-279 (Pubitemid 44301348)
33. McCubrey JA, Steelman LS, Chappell WH et al (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284 (Pubitemid 47125967)
34. Miething C, Feihl S, Mugler C et al (2006) The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib. Leukemia 20: 650-657
35. Muller MC, Lahaye T, Hochhaus A (2002) Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells. Dtsch Med Wochenschr 127: 2205-2207
36. Nicolini FE, Hayette S, Corm S et al (2007) Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. Haematologica 92: 1238-1241 (Pubitemid 350144183)
37. Nishioka C, Ikezoe T, Yang J, Yokoyama A (2010) Long-term exposure of leukemia cells to multi-targeted tyrosine kinase inhibitor induces activations of AKT, ERK and STAT5 signaling via epigenetic silencing of the PTEN gene. Leukemia 9: 1631-1640
38. Quintas-Cardama A, Cortes J (2009) Molecular biology of bcr-abl1- positive chronic myeloid leukemia. Blood 113: 1619-1630
39. Ricci C, Scappini B, Divoky V et al (2002) Mutation in the ATP-binding Pocket of the ABL Kinase Domain in an STI571-resistant BCR/ABL-positive Cell Line. Cancer Res 62: 5995-5998 (Pubitemid 35244441)
40. Rix U, Hantschel O, Durnberger G et al (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110: 4055-4063 (Pubitemid 350248462)
41. Saudemont A, Hamrouni A, Marchetti P et al (2007) Dormant tumor cells develop cross-resistance to apoptosis induced by CTLs or imatinib mesylate via methylation of suppressor of cytokine signaling 1. Cancer Res 67: 4491-4498 (Pubitemid 46815100)
42. Sharma SV, Gajowniczek P, Way IP et al (2006) A common signaling cascade may underlie ''addiction'' to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10: 425-435 (Pubitemid 44693471)
43. Soverini S, Colarossi S, Gnani A et al (2006) Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 12: 7374-7379 (Pubitemid 46095411)